Blog

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell … – TheStreet.com


Bidness ETC

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac StemCell
TheStreet.com
The stemcell therapy comes from a patient's own bone marrow and is injected into patients after a heart attack. The stem cells are then supposed to help blood flow and build cardiac muscle. NeoStem's trial used non-invasive imaging to monitor blood
Why NeoStem (NBS) Stock Might Decline TodayBidness ETC


NeoStem Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical Nasdaq

all 12 news articles »

2014-11-18 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.